Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model
Background: Cystic fibrosis (CF) is an inherited condition characterised by the abnormal transport of chloride ions across transporting epithelia. This leads to the production of thick sticky mucus in the lungs, pancreas, liver, intestine and reproductive tract, and an increase in the salt content i...
Main Authors: | P Tappenden, S Harnan, L Uttley, M Mildred, C Carroll, A Cantrell |
---|---|
Format: | Article |
Language: | English |
Published: |
NIHR Journals Library
2013-12-01
|
Series: | Health Technology Assessment |
Subjects: | |
Online Access: | https://doi.org/10.3310/hta17560 |
Similar Items
-
Use of inhaled tobramycin in patients with cystic fibrosis
by: A G Chermensky, et al.
Published: (2010-08-01) -
Sequential Inhalational Tobramycin-Colistin-Combination in CF-Patients with Chronic P. Aeruginosa Colonization - an Observational Study
by: Joachim Riethmüller, et al.
Published: (2016-08-01) -
Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
by: Lesley Uttley, et al.
Published: (2013-12-01) -
Tobramycin: efficacy of intensive therapy
by: D V Dmytriiev, et al.
Published: (2021-03-01) -
Inhaled Dry Powder Antibiotics in Patients with Non-Cystic Fibrosis Bronchiectasis: Efficacy and Safety in a Real-Life Study
by: Miguel Ángel Martínez-García, et al.
Published: (2020-07-01)